| Virology Journal | |
| The detectable anti-interferon-γ autoantibodies in COVID-19 patients may be associated with disease severity | |
| Research | |
| Chia-Hui Chou1  Tsai-Ling Liao2  Kai-Jieh Yeo3  Ching-Kun Chang3  Shih-Hsin Chang4  Joung-Liang Lan5  Po-Ku Chen6  Der-Yuan Chen7  | |
| [1] College of Medicine, China Medical University, Taichung, Taiwan;Division of Infection, China Medical University Hospital, Taichung, Taiwan;Ph.D. Program in Translational Medicine and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan;Department of Medical Research, Taichung Veterans General Hospital, Taichung, Taiwan;Rheumatology and Immunology Center, China Medical University Hospital, No. 2, Yude Road, 40447, Taichung, Taiwan;College of Medicine, China Medical University, Taichung, Taiwan;Rheumatology and Immunology Center, China Medical University Hospital, No. 2, Yude Road, 40447, Taichung, Taiwan;College of Medicine, China Medical University, Taichung, Taiwan;Ph.D. Program in Translational Medicine and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan;Rheumatology and Immunology Center, China Medical University Hospital, No. 2, Yude Road, 40447, Taichung, Taiwan;College of Medicine, China Medical University, Taichung, Taiwan;Rheumatic Diseases Research Center, China Medical University Hospital, Taichung, Taiwan;Rheumatology and Immunology Center, China Medical University Hospital, No. 2, Yude Road, 40447, Taichung, Taiwan;College of Medicine, China Medical University, Taichung, Taiwan;Translational Medicine Laboratory, Rheumatology and Immunology Center, Taichung, Taiwan;Rheumatology and Immunology Center, China Medical University Hospital, No. 2, Yude Road, 40447, Taichung, Taiwan;College of Medicine, China Medical University, Taichung, Taiwan;Translational Medicine Laboratory, Rheumatology and Immunology Center, Taichung, Taiwan;Ph.D. Program in Translational Medicine and Rong Hsing Research Center for Translational Medicine, National Chung Hsing University, Taichung, Taiwan; | |
| 关键词: SARS-CoV-2; Anti-interferon-γ auto-Abs; Titers; Disease severity; COVID-19; | |
| DOI : 10.1186/s12985-023-01989-1 | |
| received in 2022-11-10, accepted in 2023-02-08, 发布年份 2023 | |
| 来源: Springer | |
PDF
|
|
【 摘 要 】
BackgroundNeutralizing anti-interferon (IFN)-γ autoantibodies are linked to adult-onset immunodeficiency and opportunistic infections.MethodsTo explore whether anti-IFN-γ autoantibodies are associated with disease severity of coronavirus disease 2019 (COVID-19), we examined the titers and functional neutralization of anti-IFN-γ autoantibodies in COVID-19 patients. In 127 COVID-19 patients and 22 healthy controls, serum titers of anti-IFN-γ autoantibodies were quantified using enzyme-linked immunosorbent assay, and the presence of autoantibodies was verified with immunoblotting assay. The neutralizing capacity against IFN-γ was evaluated with flow cytometry analysis and immunoblotting, and serum cytokines levels were determined using the MULTIPLEX platform.ResultsA higher proportion of severe/critical COVID-19 patients had positivity for anti-IFN-γ autoantibodies (18.0%) compared with non-severe patients (3.4%, p < 0.01) or healthy control (HC) (0.0%, p < 0.05). Severe/critical COVID-19 patients also had higher median titers of anti-IFN-γ autoantibodies (5.01) compared with non-severe patients (1.33) or HC (0.44). The immunoblotting assay could verify the detectable anti-IFN-γ autoantibodies and revealed more effective inhibition of signal transducer and activator of transcription (STAT1) phosphorylation on THP-1 cells treated with serum samples from anti-IFN-γ autoantibodies-positive patients compared with those from HC (2.21 ± 0.33 versus 4.47 ± 1.64, p < 0.05). In flow-cytometry analysis, sera from autoantibodies-positive patients could also significantly more effectively suppress the STAT1 phosphorylation (median,67.28%, interquartile range [IQR] 55.2–78.0%) compared with serum from HC (median,106.7%, IQR 100.0–117.8%, p < 0.05) or autoantibodies-negative patients (median,105.9%, IQR 85.5–116.3%, p < 0.05). Multivariate analysis revealed that the positivity and titers of anti-IFN-γ autoantibodies were significant predictors of severe/critical COVID-19. Compared with non-severe COVID-19 patients, we reveal that a significantly higher proportion of severe/critical COVID-19 patients are positive for anti-IFN-γ autoantibodies with neutralizing capacity.ConclusionOur results would add COVID-19 to the list of diseases with the presence of neutralizing anti-IFN-γ autoAbs. Anti-IFN-γ autoantibodies positivity is a potential predictor of severe/critical COVID-19.
【 授权许可】
CC BY
© The Author(s) 2023
【 预 览 】
| Files | Size | Format | View |
|---|---|---|---|
| RO202305152432335ZK.pdf | 2609KB | ||
| Fig. 2 | 1339KB | Image | |
| Fig. 2 | 881KB | Image | |
| Fig. 1 | 207KB | Image | |
| Fig. 1 | 116KB | Image | |
| Fig. 1 | 409KB | Image |
【 图 表 】
Fig. 1
Fig. 1
Fig. 1
Fig. 2
Fig. 2
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]
- [40]
- [41]
- [42]
- [43]
- [44]
- [45]
- [46]
- [47]
- [48]
- [49]
PDF